Skip to main content

Table 1 Median length of the hazard period and (relative) frequency of the individuals across clinical cohort levels

From: Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival

 

Lifetime

survival

(n= 287)1

Overall survival

(n= 287)2

Progression-free

survival

(n= 284) 2

Censored

(0.12)

(0.12)

(0.23)

Lifetime

59.2

13.1

6.5

Gender

      

   Male

58.8

(0.63)

13.6

(0.63)

6.6

(0.63)

   Female

61.1

(0.37)

12.1

(0.37)

6.4

(0.37)

Race

      

   White

59.7

(0.77)

13.1

(0.77)

6.8

(0.77)

   Other

57.7

(0.23)

12.6

(0.23)

5.3

(0.23)

Therapy

      

   CRnoT

57.7

(0.40)

15.7

(0.40)

8.0

(0.34)

   R

60.7

(0.35)

12.3

(0.35)

5.3

(0.41)

   CRT

53.4

(0.10)

15.4

(0.10)

6.8

(0.10)

   Other

64.8

(0.08)

14.2

(0.08)

7.9

(0.08)

   None

70.5

(0.07)

2.9

(0.07)

1.4

(0.07)

ProgRec

      

   Yes

57.6

(0.77)

15.1

(0.77)

-

(0.77)

   No

64.8

(0.23)

5.9

(0.23)

-

(0.23)

  1. 1 expressed in years;
  2. 2 expressed in months.